SCHEMBL22221490

SCHEMBL22221490

CC(C)(Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1)C(=O)NC(c1ccccc1)c1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PPARA Q07869 5/20 0.63
▸ CNR1 P21554 16/20 0.62
▸ CNR2 P34972 9/20 0.62
▸ PPARG P37231 2/20 0.61
▸ FABP2 P12104 1/20 0.61
▸ SLC22A12 Q96S37 1/20 0.61
▸ MEN1 O00255 1/20 0.55
▸ USP2 O75604 1/20 0.55
▸ ABCB11 O95342 1/20 0.55
▸ LMNA P02545 1/20 0.55
▸ CYP1A2 P05177 1/20 0.55
▸ CYP3A4 P08684 1/20 0.55
▸ ADORA3 P0DMS8 1/20 0.55
▸ MAPT P10636 1/20 0.55
▸ CYP2C9 P11712 1/20 0.55
▸ ADRB3 P13945 1/20 0.55
▸ HPGD P15428 1/20 0.55
▸ TSHR P16473 1/20 0.55
▸ ACHE P22303 1/20 0.55
▸ SLC6A2 P23975 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22221664 0.83 CNR1 (0.65) PPARACNR1CNR2PPARGFABP2
SCHEMBL10972962 0.82 PPARA (0.64) PPARACNR1CNR2PPARGFABP2
SCHEMBL13984036 0.82 PPARA (0.64) PPARACNR1CNR2PPARGFABP2
SCHEMBL12573663 0.82 PPARA (0.70) PPARACNR1CNR2PPARGFABP2
SCHEMBL22221475 0.81 PPARA (0.67) PPARACNR1CNR2PPARGFABP2
SCHEMBL10970327 0.81 CNR1 (0.66) PPARACNR1CNR2PPARGFABP2
SCHEMBL22221437 0.80 PPARA (0.60) PPARACNR1CNR2PPARGFABP2
SCHEMBL10968550 0.80 PPARA (0.60) PPARACNR1CNR2PPARGFABP2
SCHEMBL11031297 0.80 PPARA (0.60) PPARACNR1CNR2PPARGFABP2
SCHEMBL11157333 0.79 PPARA (0.56) PPARACNR1CNR2PPARGFABP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220304957-A1 ANTI-CANCER COMPOSITIONS AND METHODS OF USE UNIV LOUISIANA STATE (US) 2022-09-29 — — US disclosed
WO-2020146876-A2 ANTI-CANCER COMPOSITIONS AND METHODS OF USE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) 2020-07-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220304957-A1 ANTI-CANCER COMPOSITIONS AND METHODS OF USE H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TP53, MCL1 PPARA 1460/4885CNR1 3125/4885CNR2 3460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback